Andrea Newkirk
Stock Analyst at Goldman Sachs
(1.17)
# 3,776
Out of 5,004 analysts
37
Total ratings
57.1%
Success rate
-3.3%
Average return
Main Sectors:
Stocks Rated by Andrea Newkirk
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Initiated Coverage: Hold | $13 | $12.65 | +2.77% | 1 | Sep 24, 2026 | |
| ALKS Alkermes | Initiated Coverage: Hold | $26 → $50 | $40.79 | +22.58% | 2 | Sep 24, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Initiated Coverage: Hold | $85 → $74 | $66.07 | +12.00% | 3 | Sep 24, 2026 | |
| INSM Insmed | Initiated Coverage: Buy | $230 → $188 | $121.55 | +54.67% | 7 | Sep 24, 2026 | |
| IOVA Iovance Biotherapeutics | Initiated Coverage: Buy | $2 → $15 | $10.80 | +38.89% | 4 | Sep 24, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiated Coverage: Buy | $154 → $337 | $236.28 | +42.63% | 2 | Sep 24, 2026 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $194 → $441 | $344.96 | +27.84% | 3 | Sep 24, 2026 | |
| MDGL Madrigal Pharmaceuticals | Initiated Coverage: Buy | $540 → $704 | $513.21 | +37.18% | 3 | Sep 24, 2026 | |
| RVMD Revolution Medicines | Initiated Coverage: Buy | $38 → $267 | $199.86 | +33.59% | 2 | Sep 24, 2026 | |
| SGMT Sagimet Biosciences | Initiated Coverage: Sell | $7 | $9.11 | -23.16% | 1 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 → $116 | $75.96 | +52.71% | 4 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $21 | $29.45 | -28.69% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.33 | n/a | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $18.44 | n/a | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.81 | n/a | 1 | Dec 4, 2024 |
AbCellera Biologics
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $13
Current: $12.65
Upside: +2.77%
Alkermes
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $26 → $50
Current: $40.79
Upside: +22.58%
Arrowhead Pharmaceuticals
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $85 → $74
Current: $66.07
Upside: +12.00%
Insmed
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $230 → $188
Current: $121.55
Upside: +54.67%
Iovance Biotherapeutics
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $2 → $15
Current: $10.80
Upside: +38.89%
Jazz Pharmaceuticals
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $154 → $337
Current: $236.28
Upside: +42.63%
Krystal Biotech
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $194 → $441
Current: $344.96
Upside: +27.84%
Madrigal Pharmaceuticals
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $540 → $704
Current: $513.21
Upside: +37.18%
Revolution Medicines
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $38 → $267
Current: $199.86
Upside: +33.59%
Sagimet Biosciences
Sep 24, 2026
Initiated Coverage: Sell
Price Target: $7
Current: $9.11
Upside: -23.16%
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $68 → $116
Current: $75.96
Upside: +52.71%
Nov 7, 2025
Reiterated: Hold
Price Target: $19 → $21
Current: $29.45
Upside: -28.69%
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $6.33
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $18.44
Upside: n/a
Dec 4, 2024
Rated: Hold
Price Target: n/a
Current: $3.81
Upside: n/a